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Propofol induces ERK-dependant expression of c-Fos and Egr-1
in neuronal cells
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aDepartment of Anesthesiology, New York Methodist Hospital, Brooklyn, New York
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Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital,
Shriners Hospitals for Children and Harvard Medical School, Boston, Massachusetts, USA

Abstract
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This study explored the effects of propofol on c-Fos and Egr-1 in neuroblastoma (N2A) cells. We
demonstrate that propofol induced the expression of c-Fos and Egr-1 within 30 and 60 min of
exposure time. At 16.8 µM concentration, propofol induced a 6 and 2.5-fold expression of c-Fos and
Egr-1, respectively. However, at concentrations above 100 µM, propofol failed to induce expression
of c-Fos or Egr-1. Propofol-induced c-Fos and Egr-1 transcription was unaffected by bicuculline, a
γ-aminobutyric acid-A receptor antagonist, but was abolished by PD98059, a mitogen-activated
protein kinase/extracellular signal-regulated kinase inhibitor. Our study shows that clinically relevant
concentrations of propofol induce c-Fos and Egr-1 expression through an extracellular signalregulated kinase mediated and γ-aminobutyric acid-A independent pathway.
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Introduction
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Propofol is a commonly used intravenous agent for the induction and maintenance of general
anesthesia used on millions of patients worldwide. It is thought to act primarily through the
hyperpotentiation of the γ-aminobutyric acid (GABA)-A receptor [1,2]. Although the GABAA dependent mechanisms are well established, there is a growing interest in elucidating
secondary mechanisms that might have long-lasting side effects [3,4]. For example, Pang et
al. [5] reported a dose-dependent effect of propofol administration on rat memory, whereas
Veselis and coworkers [6] suggested potential long-term memory effects because of changes
in cerebral blood flow. The underlying mechanism for these effects is unclear but may be
related to long-term changes in the transcriptional state of the neuronal cells.
Several groups have demonstrated that the expression of rapidly inducible genes known as
immediate-early genes (IEGs) play a critical role in long-term potentiation and memory
consolidation [7]. In particular, transcription factors, such as c-Fos, Egr-1, Nurr1, and Arc have
been implicated in learning, memory, and long-term potentiation of GABA-A receptor [8,9].
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Anesthetic agents such as midazolam and thiopental were shown to induce the transcription of
c-Fos, JunB, and Egr-1, through a GABA-A independent pathway [10,11]. However, the same
studies showed that high concentrations of propofol did not affect the expression of c-Fos,
JunB, or Egr-1 in culture [10,11]. In contrast, Hamaya et al. [12] reported that propofol
increases the expression of c-Fos and Jun B in the rat brain; whereas Kubota and coworkers
[13] showed that propofol regulates the expression of c-Fos in brain slices. Therefore, the
interaction between propofol and these immediate early transcription factors is still under
debate.
In this study, we investigated the ability of propofol to induce the transcription of c-Fos and
Egr-1 in nerve growth factor (NGF) differentiated mouse neuroblastoma (N2A) cells [14].
Using this system we demonstrate a time and dose-dependent transcription of c-Fos and Egr-1.
Remarkably, although 16.8 µM of propofol, corresponding to plasma concentrations in general
anesthesia, induced a 6 and 2.5-fold transcription of c-Fos and Egr-1, respectively, higher
concentrations failed to induce any transcriptional changes. The induction of c-Fos and Egr-1
was GABA-A independent but relied on the mitogen-activated protein kinases (MAPK)/
extracellular signal-regulated kinase (ERK) pathway. These results suggest a parallel pathway
of action with an unclear role in the activity of general anesthetics.

Methods
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Materials
Fetal bovine serum, phosphate-buffered saline, Dulbecco’s modified Eagle medium, penicillin,
streptomycin, and trypsin–EDTA were obtained from Invitrogen Life Technologies (Carlsbad,
California, USA). Propofol was purchased from AstraZeneca (Wilmington, Delaware, USA).
7S NGF, intralipid, GABA-A receptor agonists (GABA), GABA-A receptor antagonists
(bicuculline) and PD98059 were purchased from Sigma (Sigma, St Louis, Missouri, USA).
Live/Dead viability assay kit was purchased from Molecular Probes (Eugene, Oregon, USA).
Cell culture and treatment
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N2A cells (American Type Culture Collection) were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum, 2% penicillin and streptomycin
(Invitrogen Life Technologies) in a humidified incubator at 37°C and 5% carbon dioxide. Cells
were seeded at a density of 5000 cells/cm2 on six-well plates in culture media supplemented
with 10 nM of NGF to induce neuronal differentiation. Following 4 days of NGF stimulation,
more than 95% of the cells appeared to be morphologically differentiated with neurites at least
twice the length of the cell diameter. At this stage N2A cells were left untreated (negative
control), treated with intralipid (vehicle control), or treated with increasing concentrations of
propofol ranging from 5.6 to 112.2 µM. The transcription of c-Fos and Egr-1 genes was
measured at several time intervals posttreatment (Fig. 1a).
Live/Dead assay
N2A cells were treated with increasing concentrations of propofol for 4 h and then washed
with phosphate-buffered saline. The cells were stained using a fluorescent Live/Dead viability
assay in which the cytoplasm of live cells accumulates green fluorescent calcein because of
esterase activity, whereas the nucleus of dead cells is labeled red by ethidium homodimer
because of loss of membrane integrity. Cells were quantified using Image J (NIH, Bethesda,
Maryland, USA).
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Analysis of c-Fos and Egr-1 transcription was carried out using Mx3000P QPCR system
(Stratagene, La Jolla, California, USA). RNA from the cells was extracted and purified using
a Qiagen’s Nucleospin RNA II kit (Valencia, California, USA) and quantified using Nanodrop
ND-1000 (Wilmington, Delaware, USA). Total mRNA (100 ng) was reverse transcribed to
cDNA using a Superscript Platinum Two-Step quantitative reverse transcription-PCR kit
(Invitrogen Life Technologies) and amplified in a Perkin Etus Thermal Cycler 480 (Applied
Biosystems Inc., Foster City, California, USA). Reported values were normalized to the
internal standard actin. The primer sequences were as follows: c-Fos, (forward) 5′GAAGGAACCAGACAGGTCCA, (reverse) 5′-TCACCCTGCCTCTTCTCAAT; Egr-1,
(forward) 5′-AGCGAACAACCCTATGAGCA, (reverse) 5′TCGTTTGGCTGGGATAACTC; Actin, (forward) 5′-GTCGTACCACTGGCATTGTG,
(reverse) 5′-CTCTCAGCTGTGGTGGTGAA.
Western blot
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Cultured N2A cells treated with propofol were incubated with lysis buffer containing 2%
sodium dodecyl sulfate, 62.5 mM Tris–Cl (pH 6.8), 10% glycerol, 0.02% bromophenol blue,
50 mM dithiothreitol on ice for 5 min. Collected cell lysates were boiled for 5 min and separated
on a 10% gradient acrylamide gel, and transferred electrophoretically to polyvinyl difluoride
membranes. Nonspecific binding of antibody was blocked with 5% nonfat dry milk.
Immunodetection was performed with c-Fos, Egr-1, phospho-specific ERK1/2, and ERK1/2
primary antibodies (1 : 2000) followed by incubation with the peroxidase-conjugated
secondary antibodies, and the blots were developed using an enhanced chemiluminescence
method. β-tubulin served as an internal protein control (1 : 2000). All antibodies were
purchased from Cell Signaling Technologies (Danvers, Massachusetts, USA).
Statistics
Data were presented as means ± SD. Pair-wise comparisons were performed using Student’s
t-test where appropriate. P values less than 0.05 were considered statistically significant.

Results
To evaluate whether N2A cells suffer damage after propofol treatment, we quantified cellular
viability. NGF differentiated N2A cells were treated with increasing concentrations of propofol
and stained using a fluorescent Live/Dead assay (Fig. 1b). Even at concentrations as high as
112.2 µM, cell viability was 87 ± 9% and not statistically different from control (P = 0.15, N
= 3). Therefore, our results show that propofol did not affect cellular viability.
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To investigate the effect of propofol on the transcription of c-Fos and Egr-1, we exposed N2A
cells to varying concentrations of propofol at increasing time intervals. The transcription of cFos (Fig. 2a) and Egr-1 (Fig. 2b) peaked between 30 and 60 min of exposure and rapidly
returned to control levels. Maximal induction of c-Fos and Egr-1 occurred following 30 min
stimulation with 16.8 µM propofol, resulting in 6.0 ± 0.5 (P = 0.008, N = 3) and 2.5 ± 0.2 fold
(P = 0.010, N = 3) increase in transcription, respectively. Surprisingly, both lower and higher
doses of propofol resulted in a significant, but submaximal induction of c-Fos transcription 2.4
± 0.3 (P = 0.028, N = 3) and 2.6 ± 0.3 (P = 0.021, N = 3) fold change for 5.6 and 28.0 µM
concentration respectively. Similarly, both lower and higher doses of propofol resulted in a
submaximal induction of Egr-1 transcription, 1.7 ± 0.2 (P = 0.021, N = 3) and 1.1 ± 0.2 (P =
0.072, N = 3) fold change for 5.6 and 28.0 µM concentration, respectively.
To further probe the dose-dependence of c-Fos and Egr-1 transcription on propofol
concentration, we exposed N2A cells to increasing concentrations of propofol for 60 min.
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Figure 3a shows that at clinically relevant concentrations (16.8 µM) propofol caused a 6-fold
induction in c-Fos transcription and a 2.5-fold induction in the transcription of Egr-1. However,
at a dose of 112.2 µM, propofol did not significantly alter c-Fos (0.96 ± 0.2; P = 0.194, N = 3)
or Egr-1 (1.07 ± 0.17; P = 0.156, N = 3) gene expression compared with control. Figure 3b and
c show that c-Fos and Egr-1 protein expression follows a similar trend to the gene transcription
and 16.8 µM propofol caused an 8-fold increase in c-Fos expression and a 3-fold increase in
Egr-1 expression.
To evaluate the role of the GABA pathway in the induction of c-Fos and Egr-1 expression we
exposed cells pretreated with GABA-A receptor agonists or antagonists to propofol (Fig. 4a
and b). Pretreatment of N2A cells with 100 µM GABA-A receptor agonist, GABA, for 60 min
did not significantly change the transcription of c-Fos (0.81 ± 0.1; P = 0.055, N = 3) or Egr-1
(0.90 ± 0.12; P = 0.060, N = 3). The expression of c-Fos and Egr-1 in GABA pretreated cells
exposed to 16.8 µM propofol was not significantly different (P = 0.281, N = 3), than cells
treated with propofol alone. N2A cells pretreated with 100 µM GABA-A receptor antagonist,
bicuculline, for 60 min did not induce the transcription of c-Fos (0.98 ± 0.18; P = 0.167, N =
3) or Egr-1 (0.83 ± 0.18; P = 0.124, N = 3) compared with control. When N2A cells pretreated
with bicuculline were exposed to propofol, it induced c-Fos (3.25 ± 0.23; P = 0.135, N = 3)
and Egr-1 (2.03 ± 0.26; P = 0.158, N = 3) gene transcription, which was not statistically different
compared with propofol treatment alone.
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To assess the involvement of the MAPK/ERK pathway in propofol induction of c-Fos and
Egr-1, we quantified ERK phosphorylation by immunoblot analysis (Fig. 4b). We show that
16.8 µM of propofol induced a 4.8 ± 0.22 fold increase in ERK1/2 phosphorylation. The
addition of PD98059, an inhibitor of MAPK/ERK pathway blocked this increase in
phosphorylated ERK. Figure 4c shows that pretreatment of N2A cells with 50 µM of PD98059
did not induce c-Fos (0.91 ± 0.19; P = 0.183, N = 3) or Egr-1 (0.82 ± 0.20; P = 0.176, N = 3)
gene transcription compared with control. However, stimulation of PD98059 pretreated N2A
cells with 16.8 µM of propofol resulted in a significantly lower c-Fos (0.55 ± 0.22; P = 0.034,
N = 3) and Egr-1 (0.50 ± 0.24; P = 0.027, N = 3) gene transcription compared with propofol
treatment alone, demonstrating the role of ERK in propofol induction of the IEGs, c-Fos and
Egr-1.

Discussion
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Previous work indicated that general anesthetics could potentially decrease cell viability,
impair DNA integrity, and provoke stress-induced apoptosis in several neuronal cell systems
[15,16]. Such cell damage could introduce confounding results to our study because of the
induction of stress and apoptotic genes. Our results show that propofol did not affect cellular
viability even at high concentrations of the drug, suggesting that the observed gene induction
was not caused because of cellular damage or stress.
The data shows a time and dose-dependent induction of c-Fos and Egr-1 expression in N2A
cells following exposure to propofol. These results are especially interesting as previous reports
suggested that propofol did not affect the expression of c-Fos and Egr-1 [10,11]. At high
concentrations our results are in agreement with Fukuda et al.’s [10] work where no significant
changes were observed in the c-Fos and Egr-1 expression in PC12 cells stimulated with 100
µM propofol for 60 min. However, our work demonstrates that propofol has a significant effect
at low concentrations. In fact, in a clinical setting, propofol concentration in the plasma is about
16.8 µM [17], and at this concentration the drug induced a 6 and a 2.5-fold increase in the
expression of c-Fos and Egr-1. These results suggest that clinically relevant doses of propofol
can potentially induce long-term changes of neuronal functions by inducing changes in the
gene expression.
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GABA-A receptor complex is a major mediator of rapid synaptic inhibition in the brain, as
well as an important drug target. It is thought that propofol acts primarily through the
potentiation of the GABA-A receptor [1,2]. However, our results show that both GABA-A
receptor agonists (GABA) and GABA-A receptor antagonists (bicuculline) did not induce cFos and Egr-1 expression in N2A cells. In addition, several studies suggest that neuronal cell
lines, such as N2A, do not possess a functional GABA-A receptor [18]. These results suggest
that propofol could potentially activate a mechanism distinct from the GABA-A pathway,
leading to c-Fos and Egr-1 expression.
MAPKs are known to be important mediators of signal transduction from the cell surface to
the nucleus in all eukaryotes [19]. MAPK/ERK pathways are activated by a wide range of
stimuli and have the ability to activate transcription factors, protein kinases as well as
cytoskeleton-associated proteins [19]. Several studies have shown that general anesthetics may
interfere with cellular targets, including MAPK/ERK pathways [20–22]. Previous reports
suggest the involvement of the MAPK/ERK pathway in the induction of c-Fos and Egr-1
expression by growth hormone [23] or midazolam [10]. Our results show that PD98059, a
MAPK/ERK inhibitor, blocked the propofol-induced c-Fos and Egr-1 expression, thus
suggesting the possible involvement of MAPK/ERK pathway in propofol-induced IEG
expression.
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Conclusion
In summary, we demonstrated that propofol induces a time and dose-dependent transcription
of IEGs, c-Fos, and Egr-1 in neuronal cells. We demonstrate for the first time that propofol
induced IEG expression was mediated through a GABA-A independent, MAPK/ERK
dependent pathway.
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Fig. 1.

(a) Schematic representation of the experimental design.
(b) Fluorescence live/dead staining of N2A cells following 4 h stimulation with vehicle control
or propofol at doses of 16.8, 28.0, and 112.2 µM. Scale bar= 100 µm. Cells were stained using
a fluorescent viability assay in which live cells are stained green because of esterase activity,
whereas the nucleus of dead cells is labeled red because of loss of membrane integrity. NGF,
nerve growth factor; qRT-PCR, quantified using quantitative reverse transcription-PCR.
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Fig. 2.

Time and dose-dependent propofol induced (a) c-Fos and (b) Egr-1 transcription in N2A cells.
Transcription of c-Fos and Egr-1 was quantified using quantitative reverse transcription-PCR.
Gene transcription is normalized to actin and nontreated controls. Data is presented as mean
± SD from three independent experiments. **P<0.01 versus nontreated control.
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Fig. 3.

Dose-dependant expression of c-Fos and Egr-1 by propofol following 60 min stimulation. (a)
The transcription of c-Fos and Egr-1 was quantified using quantitative reverse transcriptionPCR. Gene transcription is normalized to actin and to nontreated controls. Data is presented
as mean ± SD from three independent experiments. *P<0.05; **P<0.01 versus nontreated
control. (b) Representative immunoblots of c-Fos and Egr-1 protein expression following
propofol stimulation. (c) Quantification of c-Fos and Egr-1 protein expression induced by
propofol. The amount of proteins is expressed as ratio to control. *P<0.05, **P<0.01 versus
nontreated control.
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Fig. 4.

Elucidating the mechanism of propofol-induced c-Fos and Egr-1 expression in N2A cells. The
transcription of c-Fos and Egr-1 was assessed using quantitative reverse transcription-PCR.
(a) N2A cells in the presence and absence of GABA or bicuculline pretreatment were stimulated
with propofol (16.8 µM) for 60 min. Data is presented as mean ± SD from three independent
experiments. *P<0.05; **P<0.01 versus nontreated control. (b) Representative immunoblots
of ERK1/2 phosphorylation and total ERK1/2 following propofol stimulation and
quantification of ERK1/2 phosphorylation expressed as ratio to control. *P<0.05 versus
nontreated control. (c) N2A cells with or without pretreatment of 50 µM PD98059 were
stimulated with 16.8 µM propofol for 60 min and the expression of c-Fos and Egr-1 was
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measured using quantitative reverse transcription-PCR. Data is presented as mean ± SD from
three independent experiments. *P<0.05 versus propofol treatment.
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